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Background: MET is a receptor tyrosine kinase that is activated by the ligand HGF and this pathway promotes cell
survival, migration, and motility. In accordance with its oncogenic role, MET is constitutively active, mutated, or
over-expressed in many cancers. Corollary to its impact, inhibition of MET kinase activity causes reduction of the
downstream signaling and demise of cells. In myeloma, a B-cell plasma malignancy, MET is neither mutated nor
over-expressed, however, HGF is increased in plasma or serum obtained from myeloma patients and this was
associated with poor prognosis. The small-molecule, amuvatinib, inhibits MET receptor tyrosine kinase. Based on this
background, we hypothesized that targeting the HGF/MET signaling pathway is a rational approach to myeloma
therapy and that myeloma cells would be sensitive to amuvatinib.
Methods: Expression of MET and HGF mRNAs in normal versus malignant plasma cells was compared during
disease progression. Cell death and growth as well as MET signaling pathway were assessed in amuvatinib treated
primary myeloma cells and cell lines.
Results: There was a progressive increase in the transcript levels of HGF (but not MET) from normal plasma cells to
refractory malignant plasma cells. Amuvatinib readily inhibited MET phosphorylation in primary CD138+ cells from
myeloma patients and in concordance, increased cell death. A 48-hr amuvatinib treatment in high HGF-expressing
myeloma cell line, U266, resulted in growth inhibition. Levels of cytotoxicity were time-dependent; at 24, 48, and
72 h, amuvatinib (25 μM) resulted in 28%, 40%, and 55% cell death. Consistent with these data, there was an
amuvatinib-mediated decrease in MET phosphorylation in the cell line. Amuvatinib at concentrations of 5, 10, or
25 μM readily inhibited HGF-dependent MET, AKT, ERK and GSK-3-beta phosphorylation. MET-mediated effects were
not observed in myeloma cell line that has low MET and/or HGF expression.
Conclusions: These data suggest that at the cellular level MET/HGF pathway inclines with myeloma disease
progression. Amuvatinib, a small molecule MET kinase inhibitor, is effective in inducing growth inhibition and cell
death in myeloma cell lines as well as primary malignant plasma cells. These cytostatic and cytotoxic effects were
associated with an impact on MET/HGF pathway.
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Multiple myeloma (MM) is an indolent B-cell disease
that develops in the bone marrow and is associated
with osteolytic lesions in the advanced stages [1]. Des-
pite progress in prolonging myeloma patient survival,
current therapies are not curative; thus, it is imperative
that new treatments be developed for this debilitating
disease [2,3].
Survival and proliferation of myeloma cells are dependent
on the presence of a permissive microenvironment, which
includes bone marrow stroma and soluble cytokines [4-9]
such as IL-6 and HGF [8,10]. HGF is the ligand for MET
receptor tyrosine kinase. When HGF binds to and activates
MET, MET is autophosphorylated on Tyr1230, Tyr1234
and Tyr1235 located in the activation loop [11-14]. In
addition, MET has a multisubstrate docking site that is acti-
vated at Tyr1349 and Tyr1356. The phosphorylation of this
region results in the induction of MET signaling through
the activation of several downstream target pathways, in-
cluding the mitogen-activated protein kinase (MAPK) and
AKT signaling pathways [11]. HGF/MET-induced MAPK
signaling has been shown to be essential for proliferation,
migration and invasion [7,11,15,16] while the induction of
AKT signaling promotes tumor cell survival [17].
HGF/MET signaling is increasingly recognized as an
important contributor to the pathogenesis of myeloma.
Expression of both HGF and MET has been demonstrated
in most myeloma cell lines and primary patient samples
[18,19]. Studies correlating HGF levels with MM clinical
parameters such as diagnosis [20-23] disease stage, aggres-
siveness [22,24,25], prognosis [22,23,26], and response
[26-29]. Besides its effects on the malignant myeloma
cells, HGF is involved in the pathogenesis of myeloma-
related bone disease. HGF levels are increased in patients
with extensive bone lesions, and correlates with expression
of osteoclast stimulating cytokines [24]. IL-11 secretion
from osteoblasts is induced by HGF [30], and HGF in-
hibits bone morphogenetic protein-induced osteoblasto-
genesis [31].
Taken together, these clinical findings strongly support
our hypothesis that targeting the HGF/MET signaling
pathway is a rational approach to myeloma therapy. In
line with this postulate, our laboratory studies demon-
strated that genetically knocking down MET in myeloma
cell lines using short hairpin RNA and ribozyme ap-
proaches resulted in growth inhibition and demise of the
myeloma cells [32,33]. Consistent with these observations,
a decline in MET transcript and protein levels induced
by treatment with any of the transcription inhibitors
flavopiridol, cordycepin, or 8-chloro-adenosine, promoted
myeloma cell death [32-34]. Collectively, these data dem-
onstrate MET’s pivotal role in myeloma cell biology and
underscore the importance of MET targeting as a thera-
peutic strategy in MM [35].While these genetic and pharmacologic strategies sug-
gest utility of MET/HGF inhibition as therapeutic tar-
gets, these interventions are not pragmatic for clinical
use. Amuvatinib (previously known as MP470, Astex
Pharmaceuticals, Inc.) is a synthetic carbothioamide that
inhibits MET, cKIT and platelet derived growth factor
receptor (PDGFR). This small-molecule inhibitor competes
with ATP for binding at the catalytic site. In solid cancers,
amuvatinib has been shown to be effective in inhibiting
MET at low micromolar concentrations (IC50 ~5 μM) [36].
Amuvatinib is a well-tolerated, orally bioavailable drug
currently in phase II clinical trials [37,38]. Availability of a
clinical candidate, its inhibitory potential for MET kinase,
and the role of MET in myeloma cell survival provided
compelling rationales for testing the effects of amuvatinib
on myeloma cells.
In the present study, we compared mRNA levels of
MET and HGF in normal and primary myeloma plasma
cells. We investigated amuvatinib’s actions and cytotoxic
effects in primary plasma cells obtained from patients
with myeloma. To elucidate in more detail the mechan-
ism of action of amuvatinib in myeloma cells, we evalu-
ated its effect on MET activity and downstream signaling
in the myeloma cell line U266, which over-expresses
HGF. Our data demonstrate that MET receptor tyrosine
kinase may be targeted in myeloma and support the in-
vestigation of small-molecule inhibitors such as amuvati-
nib as possible therapeutic agents against this disease.
Results
Expression levels of MET and HGF mRNA in bone marrow
plasma cells of healthy donors and patients
Previously studies have correlated plasma HGF levels with
MM clinical parameters such as diagnosis [20-23] disease
stage, aggressiveness [22,24,25], prognosis [22,23,26], and
response [26-29]. While expression of both HGF and
MET transcripts has been shown to be present in mye-
loma cells [18,19] and HGF mRNA has also been demon-
strated to be expressed in bone marrow stromal cells [39]
the levels of HGF and MET mRNA in patient plasma cells
have not been well evaluated nor correlated with disease
status.
To determine the levels of MET and HGF gene expres-
sion in malignant and normal plasma cells, we analyzed
data from the Mayo Clinic Patient Dataset available in
the public domain [40,41]. The 162 samples evaluated
represented 15 healthy individuals (normal), 22 patients
with monoclonal gammopathy of undetermined signifi-
cance (MGUS), 24 with smoldering MM (SMM), 74 with
newly diagnosed MM (MM-N), and 27 with relapsed/re-
fractory MM (MM-R). Among these five groups, there
was no significant difference (P = 0.708) in the expres-
sion of MET in the CD138+ cells (Figure 1A). In con-
trast, there was a significant trend (P = 2.5 × 10-06) for
Figure 1 Expression levels of HGF mRNA, but not MET, in CD138+ cells increase progressively from healthy individuals to myeloma
patients. Publically available expression array data was Robust Multichip Average processed and plotted as boxplots of relative (A) MET and (B)
HGF mRNA log expression values in healthy donors (normal), and in patients with monoclonal gammopathy of undetermined significance (MGUS),
smoldering multiple myeloma (SMM), newly-diagnosed multiple myeloma (MM-N), or relapsed/refractory disease (MM-R). Boxplots show 25th and 75th
percentiles and the bold lines as medians. Whiskers show the range of values within the interquantile range from the box, and circles are outliers.
Numbers at the bottom of each graph indicate the number of individuals in each category.
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with progressive severity of disease from healthy donors
to patients with relapsed or refractory MM (Figure 1B).
Within each group, there was heterogeneity in HGF
expression as evinced by the 75th percentile mark. It is
interesting to note that even samples with lower HGF
mRNA levels in the plasma cells, typically had higher
levels than the samples from healthy individuals; the
25th percentile for the myeloma patient HGF levels was >
the 75th percentile for healthy individuals.
Induction of apoptosis by amuvatinib in primary CD138+
and CD138– Cells
Gene array analysis along with numerous other studies
by us [32,33] and others [22,23,26], identified the HGF/
MET axis as a therapeutic target in myeloma. To test
this, we assessed the sensitivity of primary myeloma cells
to the MET-kinase inhibitor, amuvatinib. CD138+ (mye-
loma plasma cells) and CD138– (non-malignant cells)
cells were isolated from bone marrow samples obtained
from eight myeloma patients (Table 1) and treated with
25 μM amuvatinib for 24 h. This dose was chosen based
on findings that >95% of the compound is bound and se-
questered by serum proteins (unpublished data) as well
as a small preliminary screen in myeloma cell lines (data
not shown). CD138+ cells from six out of eight patient
samples showed a cell death induction in the amuvatinib
treated cells compared to time-matched dimethyl sulfox-
ide (DMSO)-treated control cells as measured by
annexin V/propidium iodide (PI) staining (Figure 2A).
Cell death in these six samples increased by 20% to 67%
compared to time-matched controls; patients 3 and 5
showed <10% increase in cell death.
An assessment of clinical characteristics of the mye-
loma patients did not reveal any correlations with
amuvatinib-induced cell death, including prior treat-
ment, patient age, or cellularity of the bone marrow
(Table 1). We were able to measure the HGF levels in
plasma samples from patients 2, 4, and 5 which wereTable 1 Myeloma patient characteristics
Pt # Age (yrs) Sex Ethnicity WBCa (103/μl) Plasma cells (%) BM
1 62 Male White 3.6 7 At
2 53 Female Black 2.0 74 Po
de
3 53 Female White 6.3 4 Po
4 76 Female White 4.4 2 Po
de
5 58 Female Hispanic 9.1 8 At
6 64 Female White 12.5 49 At
7 71 Male White 3.9 32 NA
8 76 Male White 4.9 36 po
awhite blood cells; bbone marrow; cnot applicable.11.9, 1.7, and 1.4 ng/mL, respectively. Although the
number of total samples is small, there seems to be a
relationship between levels of HGF and amuvatinib-
induced apoptosis. Additional studies are needed to de-
termine if there is any correlation between HGF level
and sensitivity of CD138+ cells to MET inhibition.
In contrast to the sensitivity of CD138+ cells to amu-
vatinib, CD138– cells did not show any sizeable induc-
tions (all, <10%) of death compared to time-matched
controls (Figure 2B), suggesting that non-malignant bone
marrow cells are not affected by amuvatinib. Overall, these
results indicate that treatment of CD138+ MM cells with
a MET inhibitor is detrimental to their survival.
Effect of Amuvatinib on MET signaling in CD138+ and
CD138- cells
To determine whether death of CD138+ cells was associ-
ated with an effect on the target, total and phosphorylated-
MET (p-MET) expression levels were determined by flow
cytometry. There were sufficient numbers of cells from pa-
tients 6 and 8 to perform this assessment. In both samples,
MET phosphorylation was reduced on Tyr 1234/1235 in
the CD138+ cells by 40% and 50%, respectively, as com-
pared to the time-matched controls (Figure 3A and B).
In contrast, there was no detectable level of p-MET in
CD138– cells from patient 8 as compared to isotype con-
trol (Figure 3C). The lack of p-MET in CD138– cells likely
explains why this population of cells was not affected by
amuvatinib treatment in any of the eight patient samples.
Effect of Amuvatinib on Growth Inhibition
Since the number of the primary CD138+ cells in eight
patient samples were insufficient for performing a de-
tailed investigation of HGF/MET signaling, we decided
to further investigate the effects of amuvatinib in a mye-
loma cell line. Because our results in the patient samples
suggested that higher levels of HGF may be associated
with an increased sensitivity to MET inhibition, we used
the U266 cell line which expresses high levels of HGFb aspirate done Outcome of treatment
diagnosis NAc
st bortezomib + doxorubicin + lenalidomide +
xamethasone
Progressive
st 3 cycles bortezomib + dexamethasone Near complete remission






st 1 yr auto stem cell transplant Progressive
Figure 2 Amuvatinib induces apoptosis in CD138+, but not CD138– cells. (A) CD138+ and (B) CD138– cells isolated and purified from bone
marrow samples of eight myeloma patients were stained with annexin V/PI and assessed by flow cytometry initially after isolation (white bars) or
after 24 h of treatment with vehicle (gray bars) or 25 μM amuvatinib (black bars).
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amuvatinib-treated U266 cells showed a dose- and time-
dependent decrease in growth (Figure 4A). The growth
inhibition was ~40% at a dose of 5 μM after 48 and 72 h
of incubation and 50% at a dose of ~7 μM at 72 h.
Effect of Amuvatinib on cell cycle arrest and DNA
synthesis
We also tested whether the observed amuvatinib-
induced growth inhibition was associated with an alter-
ation in the cell cycle. At low micromolar doses (3 and
5 μM), U266 cells were arrested at G1 after 48 and 72 h
(Figure 4B and C). In the DMSO-treated controls, ap-
proximately 65% of cells were in G1 phase at 72 h, while
cells treated 3 μM amuvatinib significantly increased to
75% in G1 phase at the same time point (p < 0.05). Incu-
bation with a higher level of amuvatinib (25 μM) re-
sulted in a lower percentage of cells in G1 phase
(Figure 4C), with a concomitant increase in the subG1
fraction (data not shown).To determine whether the observed cell cycle changes
were associated with an effect on DNA synthesis, we
measured incorporation of thymidine in total DNA.
Compared to DMSO-treated (control cells), amuvatinib-
treated cells had decreased thymidine incorporation at
doses of both 5 and 25 μM (Figure 4D), which was sig-
nificantly higher for cells treated with 5 μM amuvatinib
for 24 and 72 h, (P = 0.008 and P = 0.048, respectively).
At 24 h, the inhibition of thymidine incorporation was
greater than 50% with 5 μM amuvatinib. Additionally, as
expected, the decrease in the cells’ S-phase DNA replica-
tive capacity was discernible 24 h before there was a
measurable change in the cell cycle profile as the doub-
ling time for U266 cells is ~36 hours.
Induction of Apoptosis by Amuvatinib
Similar to what was seen in the primary CD138+ cells,
U266 cells treated with 25 μM amuvatinib exhibited sig-
nificantly greater cell death (28%, 40%, and 54%) than
DMSO-treated controls (6%, 7%, and 7%) for 24, 48, and
Figure 3 Amuvatinib treatment decreases phospho-MET pro-
tein in freshly obtained CD138+ cells. (A) Flow cytometric
analysis of the levels of p-MET (Tyr1234/Tyr1235) in CD138+ cells
from patients 6 and 8 after 24 h treatment with (thick black line) or
without (gray shaded peak) 25 μM amuvatinib. (B) p-MET and total
MET were quantified in untreated (white bars) and 25 μM amuvati-
nib treated cells (hashed bars) from panel (A) along with total MET
levels in untreated (black bars) and 25 μM amuvatinib treated cells
(diagonal bars). (C) Plot represents the levels of p-MET (Tyr1234/
Tyr1235) in CD138– cells from patient 8 24 h after treatment with
(thick black line) or without (gray shaded peak) 25 μM amuvatinib,
and secondary only control (dashed line).
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and 0.018 respectively). This apoptotic induction was
blocked by a pan-caspase inhibitor, ZVAD, suggesting a
role for caspases in amuvatinib-mediated cell death (data
not shown). Consistent with the annexin V/PI staining
results was our finding that amuvatinib induced poly
ADP ribose polymerase (PARP) cleavage in these cells in
a dose-dependent manner. Under full serum conditions
(10% fetal bovine serum (FBS)), an induction of PARPcleavage was seen after 24 h with doses as low as 3 μM
amuvatinib with the highest level of cleaved PARP prod-
uct was seen at 25 μM (Figure 5C).
Because 95% of amuvatinib binds serum proteins and
is unavailable to the cells, we also examined the efficacy
of amuvatinib under low serum (0.1% FBS) conditions.
When cells were treated with 5 μM amuvatinib for
16 hours in the presence of low serum, but in the pres-
ence of endogenous autocrine HGF, we found maximum
induction of PARP cleavage (Figure 5D). To further con-
firm the cytotoxic effects of amuvatinib in myeloma cells
is associated with inhibiting the HGF/MET signaling
axis, we compared the efficacy of amuvatinib to induce
apoptosis in U266 cells versus RPMI-8226/S, a myeloma
cell line which express 75% lower levels of HGF and 95%
lower levels of MET (Additional file 1: Figure S1). As ex-
pected, there was a significant amuvatinib dose-
dependent apoptosis-induction in the U266 cells after
48 h treatment (Figure 5E) (25 μM versus 0, 2.5, 5, and
10; P = 0.022, 0.018, 0.013, and 0.029, respectively). In
contrast there was only a minor apoptosis induction in
the RPMI-8226/S cells which was not statistically signifi-
cant (P = 0.053, 0.300, 0.427, and 0.503, respectively).
These results suggest that the apoptosis induction is due
to targeting MET kinase which U266 cells are addicted
to while RPMI-8226/S cells are not.
Tumoricidal Effects of Amuvatinib in Myeloma Cells
Grown in a Protective Stromal Environment
Bone marrow stroma provides a protective environment
for MM cells [42]; thus, it is important to assess the effi-
cacy of therapeutic agents in the context of a stromal
environment. To assess this, we treated U266 cells co-
cultured with and without stromal cells with amuvatinib
for 48 h and measured viability by using flow cytometry
analysis of annexin V/PI staining. Under these condi-
tions, the U266 do not attach to the stromal cells, but
are protected by them through both cell to cell contact
and by various soluble factors produced by the stromal
cells [43]. Amuvatinib induced ~50% cell killing during
this time period and co-culture with the stromal cells
provided no protection from this effect (Figure 5F). In
contrast, these stromal cells were able to protect U266
cells from bortezomib treatment as they reduced the
amount of bortezomib-induced apoptosis from ~75%
to ~40% (Additional file 1: Figure S2A). To determine
whether amuvatinib had an effect on the survival of stro-
mal cells, stromal cells cultured alone were treated with
amuvatinib, harvested by trypsinization, and similarly
assessed for viability. Interestingly, amuvatinib had a
very minimal effect on the survival of this population of
cells (Figure 5F), though they express MET (Additional
file 1: Figure S2B). These results indicate that the tumor-
icidal action of amuvatinib was largely restricted to the
Figure 4 Amuvatinib inhibits growth, induces cell cycle arrest, and inhibits DNA synthesis in myeloma cell line U266. (A) U266 cells
were treated with amuvatinib at various concentrations for 24 (■), 48 (▲), and 72 h (▼). Cells were counted using a Coulter counter, and the
effect of the treatment on cell growth was determined. The data are presented in a time- and dose-dependent manner as percentages of
time-matched controls. Data are representative of three independent experiments and presented as Mean ± SEM, n = 3, *P < 0.05. (B) To
determine the effect of amuvatinib on the cell cycle, U266 cells were treated with 3 or 5 μM amuvatinib or DMSO for 72 h. Flow cytometry was
used to assess the DNA content of cells stained with PI, regions labeled M1, M2, M3, and M4 represent cells in Sub-G1, G1, S, and G2/M phases of
the cell cycle, respectively. (C) Cell cycle analyses were performed as in panel (B), with treatments for 24 (white bars), 48 (gray bars), and 72 h
(black bars) and the percentage of cells in the G1 phase of the cell cycle were plotted. Data are representative of three independent experiments
and presented as Mean ± SEM, n = 3, *P < 0.05. (D) The effect of amuvatinib on DNA synthesis was determined by treating U266 cells with DMSO
or 5 and 25 μM amuvatinib for 24 (white bars), 48 (gray bars), and 72 h (black bars) and quantifying thymidine incorporation. The data are
presented as percentages of time-matched controls. Data are representative of three independent experiments and presented as Mean ± SEM,
n = 3, *P < 0.05, **P < 0.01.
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not addicted to MET, are not affected by this inhibitor.
Furthermore, the stromal cells were not able to protect
the U266 cells from amuvatinib’s tumoricidal activity.
Since amuvatinib also inhibits PDGFR and KIT, we vali-
dated MET kinase inhibition as the primary cause of cell
death by using imatinib as a negative control. In addition
to ABL, imatinib is known to also inhibit PDGFR and KIT
but not MET [44]. In contrast to amuvatinib, 25 μM ima-
tinib did not induce significant cell death (Figure 5G; P =
0.07) indicating that amuvatinib-mediated cell death is not
due to its effects on PDGFR and KIT.Effect of Amuvatinib on MET Protein
To further investigate the effect of amuvatinib on MET
signaling, we first measured MET receptor tyrosine kin-
ase activity in U266 cells by flow cytometry. Similar to
the results seen with the CD138+ cells from the patient
samples, a reduction in MET phosphorylation was de-
tected in cells treated for 24 hr with 25 μM amuvatinib
when cells are grown in normal growth conditions (10%
FBS) (Figure 6A and B). This decrease of p-MET was as-
sociated with cell death as cell death was induced with
25 μM amuvatinib when cells are grown in normal
growth conditions (10% FBS) (Figure 5B).
Figure 5 Amuvatinib is tumoricidal to U266 myeloma cells. Apoptosis was quantified by staining cells with annexin V/PI and measuring
staining positivity using flow cytometry. (A) A representative annexin V/PI staining profile 72 h after treatment with 25 μM amuvatinib or DMSO is
shown. (B) U266 cells were treated with DMSO or various concentrations of amuvatinib for 24 (white bars), 48 (gray bars), and 72 h (black bars)
and percent of annexin V/PI positivity is presented. Data are representative of three independent experiments and presented as Mean ± SEM,
n = 3, *P < 0.05. Immunoblot analysis demonstrating cleavage of PARP protein after treatment with amuvatinib at indicated concentrations under
conditions of (C) full serum (10% FBS) for 24 h, or (D) serum starved conditions with endogenous HGF for 16 h, (E) U266 and RPMI-8226/S cells
were treated with various concentrations of amuvatinib for 48 h and percent of annexin V/PI positivity is presented. Data are representative of
three independent experiments and presented as Mean ± SEM, n = 3, *P < 0.05. (F) U266 cells cultured alone (black bars), or on NK-tert stromal
cells (gray bars), or stromal cells alone (white bars), were treated with or without 25 μM amuvatinib for 48 h and assessed by flow cytometry for
annexin V/PI staining. (G) Cells were treated with various concentrations of imatinib and annexin V/PI positivity is presented as percentage of
time-matched controls. Data are representative of three independent experiments and presented as Mean ± SEM, n = 3, *P < 0.05.
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naling, protein lysates from U266 cells serum starved in
0.1% FBS for 16 h with and without various concentra-
tions of amuvatinib followed with 15 min HGF stimula-
tion were examined by immunoblot analysis. The results
showed that under serum starved conditions, treatment
with 5 μM amuvatinib, decreased phosphorylation of the
processed ~140 kDa MET β-chain at Tyr1349 by ~60%
(Figure 6C and D). Because of the autocrine stimulation of
MET by the endogenous HGF produced in these cells,MET was phosphorylated under serum-starved con-
ditions even without the addition of exogenous HGF.
Furthermore, an amuvatinib-dependent decrease of total
MET levels of ~30% was also observed. A ~170 kDa
phosphorylated MET band was detected at ~2 fold
higher levels than the 140 kDa band in untreated U266
cells. A comparison with total MET shows both bands
were present but the levels of the total 140 kDa band
was ~4 times greater than the levels of the 170 kDa
band. Although unprocessed pro-MET, containing both
Figure 6 Amuvatinib suppresses MET receptor tyrosine kinase activity. (A) Flow cytometry analysis of p-MET (Tyr1234/1235) levels in U266
cells were treated for 24 hrs with DMSO (gray shaded) and 25 μM amuvatinib (dark black line). (B) Quantification of phospho (black bars) and
total (gray bars) MET staining in U266 cells treated with the indicated concentrations of amuvatinib (Rx) from quadruplet experiments as in (A).
(C) U266 cells were serum starved and treated with the indicated concentrations of amuvatinib or DMSO and stimulated with 50 ng/ml HGF for
15 min. Cell lysates were subjected to immunoblot analysis to assess MET (Y1349) phosphorylation. (D) The 140 kDa (solid bars) and the 170 kDa
(speckled bars) phospho (black bars) and total (gray bars) MET bands from triplicate experiment as in (C) were quantitated and normalized to
GAPDH levels. The results are presented as percentages of the HGF-stimulated DMSO controls. Data are representative of three independent
experiments and presented as Mean ± SEM, n = 3, *P < 0.05, **P < 0.01.
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as a 170 kDa band, it has not been associated with kinase
activity. Conversely, a splice variant of MET containing an
additional 54 nt of exon 10 has been reported to be
expressed at low levels [45]. This splice form produces aMET isoform that has kinase activity, though it cannot be
processed into α and β subunits. In U266 cells, amuvatinib
inhibited phosphorylation of a 170 kDa MET by ~70%
(Figure 6C and D, B). Again, the decrease of HGF-specific
phosphorylation of both isoforms of MET under low
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serum conditions (Figure 5D). The lower concentration of
amuvatinib needed to decrease MET phosphorylation
under 0.1% serum versus 10% serum conditions is in
agreement with binding of the drug by serum proteins.
Additionally, the concentration of amuvatinib required to
decrease MET phosphorylation correlates with the concen-
tration required to induce cell killing under either growth
conditions. These results suggest the amuvatinib-induced
cell death was associated with reduced METactivity.
Effect of Amuvatinib on downstream targets of MET
Previous studies have shown that inhibition of MET
causes a reduction in the phosphorylation of both AKT
and extracellular signal-regulated kinases (ERK)1/2 in
the MAPK signaling pathway [11]. The regulation of
AKT activity by MET plays a prominent role in promot-
ing cell survival. Moreover, MET regulation of the ERK
pathway is important for proliferation and both the
ERK1/2 and AKT pathways are involved in MET-
induced cell spreading and motility. To examine AKT
activity, p-AKT (S473) levels were measured in U266
cells by flow cytometry. Similar to the results seen with
p-MET, a reduction in AKT phosphorylation was de-
tected in cells treated for 24 hr with 25 μM amuvatinib
when cells were grown in normal growth conditions
(10% FBS) (Figure 7A and B). An assessment of amuvati-
nib’s effects on HGF-specific signaling was also per-
formed in the U266 cells cultured in 0.1% FBS for 16 h
with and without various concentrations of amuvatinib
followed with 15 min HGF. Immunoblot analysis again
showed that lower concentrations amuvatinib is needed
to decreased AKT phosphorylation at Ser473 (Figure 7C
and D), even though in these cells the levels were low
and difficult to detect. Interestingly, total AKT decreased
by 60% with amuvatinib treatment. To better assess the
effect of amuvatinib on the AKT pathway, we examined
the phosphorylation of an AKT target, glycogen synthase
kinase 3 β (GSK3β) on Ser9. Amuvatinib-treated cells
showed, in addition to reduction of AKT, a 65% decrease
in phosphorylation of GSK3β, with a 24% decrease in
total GSK3β (Figure 7C and E).
A similar assessment of phospho-ERK1/2 levels under
HGF specific signaling demonstrated that amuvatinib
inhibited phosphorylation of both the 44-kDa and the
42-kDa ERK isoforms by 55% and 50%, respectively,
while total ERK1/2 levels did not significantly change
(Figure 7C and F). These results demonstrate that amu-
vatinib treatment inhibits both ERK1/2 and AKT signal-
ing through the MET pathway.
Discussion
MET is a receptor tyrosine kinase that is activated by
the ligand HGF and has been shown to be constitutivelyexpressed, mutated, or over-expressed in many different
cancer cell types. It serves as an important factor for cell
survival, migration, and motility [7,11,15]. Corollary to
that, inhibition of MET kinase activity causes reduction
of the downstream signaling that is necessary for these
cells to maintain their oncogenic properties [46]. Pre-
vious studies in our laboratory showed that while MET
receptor tyrosine kinase acts as a survival factor for
myeloma cells [32,33], it is neither mutated nor, for the
most part, over-expressed in MM. However, its ligand
HGF is increased in plasma or serum obtained from
myeloma patients and higher HGF level has been associ-
ated with poor prognosis [18,20,22,26]. Furthermore,
HGF not only promotes growth, migration, and survival
of myeloma cells, it also potentiates IL-6 effects [46].
While levels of plasma HGF have been associated with
myeloma, levels of HGF and MET mRNA in patient
plasma cells have not been well evaluated nor correlated
with disease status. Our analyses of mRNA array data
[40,41] demonstrated autocrine expression of HGF in
CD138+ plasma cells from MM patients. This was con-
sistent with previous report in 7 myeloma patient sam-
ples [18]. Our results further elucidated that the level of
the HGF expression was directly associated with disease
progression.
Together, these findings provide a rationale for target-
ing the HGF/MET signaling axis in myeloma. Targeting
HGF directly may prove difficult, since therapeutic tar-
geting of HGF would need to be effective at elevated
levels to successfully compete and inhibit the high serum
HGF concentrations in myeloma patients. Therefore,
using a small-molecule MET suppressor such as amuva-
tinib may be a viable option to target the HGF/MET
pathway. Additionally, several MET inhibitors are avail-
able for clinical testing [11].
Amuvatinib is an orally available drug that is currently
in clinical trials for the treatment of solid tumors
[37,38,47]. This compound was designed, developed,
and selected via a computation-driven in silico process
whereby drug scaffolds were screened, docked, and fitted
against a homologous model of KIT. After additional
screening in biochemical and cell-based assays, amuvati-
nib was selected as a tyrosine kinase inhibitor with activ-
ity against wild-type and mutant KIT, MET, RET, FLT3
and PDGFRα [48,49]. Later, amuvatinib inhibition of
MET activity was found to lead to reduction of RAD51
expression and to radiosensitization of tumor cells [50].
Since amuvatinib is a small-molecule inhibitor that
suppresses MET activity, we tested this agent as a proof-
of-concept to therapeutically target MET in myeloma.
Our study demonstrated that amuvatinib was effective in
inhibiting growth and DNA synthesis at low micromolar
concentrations in cell lines grown under normal condi-
tions (10% FBS). Moreover, amuvatinib treatment resulted
Figure 7 Amuvatinib inhibits MET signaling. (A) Flow cytometry analysis of p-AKT (Ser473) levels in U266 cells were treated for 24 hrs with
DMSO (gray shaded) and 25 μM amuvatinib (dark black line). (B) Quantification of phospho (black bars) and total (gray bars) AKT staining in U266
cells treated with the indicated concentrations of amuvatinib (Rx) from five experiments as in (A). (C) U266 cells were serum starved, treated with
the indicated concentrations of amuvatinib or DMSO, and stimulated with 50 ng/ml HGF for 15 min. Cell lysates were subjected to immunoblot
analysis to assess phosphorylation of ERK p44/42, AKT, and GSK-3β. AKT (D), GSK-3β (E), and ERK p44 (solid bars) and p42 (speckled bars) (F),
phospho (black bars) and total (gray bars) bands were quantitated and normalized to GAPDH levels. The results are presented as a percentage of
the HGF stimulated DMSO control. Data are representative of three independent experiments and presented as Mean ± SEM, n = 3, *P < 0.05.
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MET/HGF signaling, as measured by annexin V/PI stain-
ing and PARP cleavage. This cytotoxic effect remained
even when these MET-addicted cells were grown on bone
marrow stromal cells. In contrast, the drug did not induce
apoptosis in another myeloma cell line (RPMI-8226/S)
that is not dependent on the MET/HGF signaling axis due
to lower levels of HGF (75% less) and MET (95% less).
Because amuvatinib also impairs KIT and PDGFR sig-
naling, we tested impact of imatinib (an established KIT
and PDGFR inhibitor) in myeloma cells. Imatinib in-
duced no significant amount of cell death in U266 cells
demonstrating that amuvatinib’s effect was due to MET
inhibition. This statement was in line with the data
regarding decreased phosphorylation of MET after amu-
vatinib treatment. Because >95% of the compound is
bound and sequestered by serum proteins (Unpublished
data), the dose required to achieve maximum inhibition
of MET phosphorylation in serum starved conditions
was lower than the dose to induce apoptosis in full
serum conditions. Likewise, under serum starved condi-
tions, the maximum induction of apoptosis was seen at
the same dose which achieved maximum inhibition of
MET phosphorylation. As expected, in imatinib treated
cells, there was no reduction of p-MET (data not shown)
as well as no significant reduction in survival. These cor-
relation data suggest that amuvatinib mediated growth
inhibition and cell death is due to its action on MET and
not its action on KIT or PDGFR.
In conjunction with a decrease in MET phosphoryl-
ation, there was a decline in HGF-dependent ERK1/2
and AKT phosphorylation as well as the phosphorylation
of the AKT targets GSK3β and caspase-9 (data not
shown). Diminution of phosphorylated MET and associ-
ated decreases in ERK1/2 and AKT phosphorylation has
been shown to be important in growth, migration and
cell survival pathways for other cancer cell types [11].
Amuvatinib proved to be effective in inducing cell death
not only in a MET dependent myeloma cell line but also
in primary CD138+ malignant plasma cells obtained from
patients with myeloma. In contrast, amuvatinib did not
cause cell death in normal CD138– cells obtained from the
same individuals (Figure 2). These data provide evidence of
the selectivity of amuvatinib, suggesting that it may be used
specifically for myeloma treatment without impairing other
normal hematological cells in the bone marrow. In line
with this selective cytotoxic effect on CD138 plasma cells,
MET phosphorylation was reduced by amuvatinib treat-
ment in primary plasma cells but not CD138– cells.
The effects of amuvatinib described here provide
proof-of-concept that MET is important for the survival
of myeloma cells and that reduction of its kinase activity
may prove to be an effective targeted therapy. The 25 μM
dose of amuvatinib needed to robustly induce apoptosis incell lines and plasma cells under full serum conditions
may not be achievable in vivo. Pharmacokinetic studies of
amuvatinib during a phase I trial indicated that plasma
levels reached between 1 and 2 μM [51]. Hence, newer
generation and more potent MET tyrosine kinase inhibi-
tors are needed [11]. ARQ 197 (tivantinib) is a small-
molecule, non-ATP-competitive inhibitor which is highly
specific for MET [52,53]. This drug is well tolerated in
clinical trials and has shown efficacy in solid tumors
[54-58]. Pharmacodynamic studies from a phase I trial in-
dicated that at an oral dosing of 360 mg, twice daily, ARQ
197 reached steady-state plasma concentrations of 6–7 μM
[55]. This correlated with decreases in total MET and
phospho-FAK (Tyr861) and increases in TUNEL-positive
cells in patients’ tumors.
Our results with amuvatinib provided the impetus to
pursue testing of ARQ 197 in myeloma cells. Our preclin-
ical studies indicated that treatment with ARQ 197 for
48 hours was cytotoxic to myeloma cell lines (≥ 60%
increase in annexin V/PI-positive cells) at clinically achiev-
able doses [59]. Moreover, these studies provided the
foundation for a Cancer Therapy Evaluation Program,
National Cancer Institute sponsored phase 2 clinical trial
of ARQ 197 in myeloma patients, which is currently un-
derway at MD Anderson Cancer Center [60].
Conclusions
Our finding provides proof-of-principle that MET is im-
portant for the survival of myeloma cells and using a
MET inhibitor such as amuvatinib may prove to be an
effective strategy for treatment of MM. Amuvatinib ex-
hibited tumoricidal activity in myeloma cells which was
associated with inhibition of MET signaling. Amuvatinib’s
lack of effect on CD138– cells from the same patients fur-
ther establishes the selectivity of this agent. The clinical
success of other targeted therapeutics for cytoplasmic and
receptor tyrosine kinases, further underscores a need for
testing a small-molecule inhibitor that targets MET kinase
activity for patients with myeloma.
Methods
Materials
Amuvatinib (MP470) was obtained from Astex Pharma-
ceuticals, Inc. (Dublin, CA) and was dissolved in DMSO
(Sigma Aldrich, St. Louis, MO). Because of stability
constraints, amuvatinib solution was prepared fresh for
each experiment. Imatinib was purchased from Novartis
(St. Louis, MO) and was dissolved in DMSO and stored
in aliquots at -20°C. [3H] thymidine (60 Ci/mmol) was
obtained from Moravek Biochemical Inc. (Brea, CA).
Cell culture and growth analysis
The myeloma cell lines U266 [61] and RPMI-8226/S
[62] were obtained from Dr. William Dalton at H. Lee
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bone marrow stromal cells were obtained from Dr. Jan
Burger at UT MD Anderson Cancer Center [63]. The
cell lines were maintained as described [32,63] and rou-
tinely tested for Mycoplasma infection and authenticated
by short tandem repeat analysis by UT MD Anderson
Cancer Center’s Characterized Cell Line Core facility.
Myeloma cell-stromal co-cultures were performed using
U266 cells and NK-tert cells at a ratio of 20 to 1. Stromal
cells were plated at a concentration of ~2 × 102 cells/mm2
surface area 5 hours before adding U266 cells at a 20 fold
higher concentration. The cells were co-cultured for 2 h
prior to treatment with or without amuvatinib or bortezo-
mib for 48 h. At the end of incubation, the U266 cells,
which are free floating in these cultures, were carefully
removed for analysis, leaving the adherent stromal layer
undisturbed. Additionally, the stromal cells were also har-
vested by trypsinization and similarly assessed.
The effect of amuvatinib treatment on cell growth
inhibition was measured in exponentially growing
U266 cells. Cells were counted using a Coulter counter
(Beckman Coulter, Fullerton, CA). DNA synthesis was
measured using [3H]thymidine incorporation as de-
scribed [64].
Gene expression array analyses
Expression data from 162 CD138+ bone marrow plasma
cell samples from healthy individuals as well as patients
with MGUS, SMM, MM-N, and MM-R, which were mea-
sured by using Affymetrix U133A microarrays, were down-
loaded from GEO (GSE6477) [40,41]. Robust Multichip
Average (RMA) algorithm was used for normalization/
quantification of the data. The maximal values for the re-
spective probe-sets of MET and HGF were used for gene
expression profiling. The Kruskal-Wallis test was applied
to assess whether expression of MET and HGF was associ-
ated with defined clinical groups, and results are presented
as box-plots.
Isolation of CD138+ AND CD138– cells from primary bone
marrow aspirates from MM patients
Primary samples were obtained from both male and
female myeloma patients being treated at MD Anderson
Cancer Center (Table 1). Patient samples were obtained
using an MD Anderson Cancer Center Institutional
Review Board approved protocol. All patients signed an
informed consent form to provide peripheral blood and
bone marrow samples. After collection of bone marrow
samples, CD138+ cells were isolated as described [65],
suspended in RPMI 1640 with 10% human AB serum
(Cambrex Biosciences, East Rutherford, NJ) and used
immediately for experiments. Peripheral blood samples
were collected from patients 2, 4, and 5 for assessment
of plasma HGF levels.Immunoblot analysis
The effects of amuvatinib on HGF dependent signaling
were assessed in U266 cells that had been serum starved
for 24 h in RPMI 1640 containing 0.1% FBS; for the last
16 h of starvation the cells were treated with various
concentrations of amuvatinib or DMSO. They were then
treated with 50 ng/ml HGF for 15 min to stimulate
MET. Amuvatinib-mediated induction of PARP cleavage
was performed on U266 cells cultured in full serum
(10% FBS) as well as under low serum conditions (0.1%
FBS). Protein lysates and immunoblots were prepared as
previously described [66]. Experiments were performed
in triplicates, and bands were quantified by using an
Odyssey Infrared Imaging System (LI-COR Biosciences,
Lincoln, NE). Primary antibodies were: mouse monoclo-
nal antibodies to MET clone 3D4 (Invitrogen, Carlsbad,
CA); GSK-3β clone 7/GSK-3b, PARP clone C2-10,
cleaved PARP Asp 214 clone F21-852, AKT clone 9Q7
(BD Biosciences Pharmingen, San Diego, CA); GAPDH
clone 6C6 (Abcam, Inc, Cambridge, MA); phospho-
ERK1/2 (Thr202/Tyr204) clone E10 (Cell Signaling
Technology, Danvers, MA); β-actin clone AC-15 (Sigma
Aldrich); rabbit monoclonal antibodies to phospho-GSK-
3β (Ser9) clone 5B3 (Cell Signaling Technology); rabbit
polyclonal antibodies to phospho-MET (Tyr1349) (Invi-
trogen); ERK1/2, and phospho-AKT (Ser473) (Cell Sig-
naling Technology).
Flow cytometry
Intracellular protein expression in U266 cells was mea-
sured using BD Cytofix/Cytoperm Fixation/Perme-
abilization Kit (BD Biosciences). Primary antibodies
used were anti-phospho-HGF R/c-MET (Tyr1234/
1235) (R&D Systems, Minneapolis, MN), MET (C-12):
sc-10 (Santa Cruz Biotechnology, Santa Cruz, CA),
phospho-AKT (Ser473), AKT antibody (Cell Signaling
Technology); and caspase-9 (Ser196) (Santa Cruz
Biotechnology). Secondary antibody was a fluorescein
isothiocyanate–conjugated (FITC) Affinipure goat anti-
rabbit (Jackson ImmunoResearch, West Grove, PA). Cell
cycle analysis and annexin V/propidium iodide (PI) stain-
ing were performed, respectively, as described [32,33]. All
flow cytometry analysis was performed using a Becton
Dickinson FACSCalibur flow cytometer (San Jose, CA,
USA). Statistical significance of changes was assessed by
paired t-test analysis using Prism software (Graphpad, San
Diego, CA).
Enzyme linked-immuno-sorbent assay for HGF levels
HGF levels in primary patient plasma were determined
using the Human HGF Immunoassay Kit as per the
manufacturer’s protocol (Invitrogen). The absorbance of
this horseradish-peroxidase based assay was measured at
450 nm. Each sample was assayed in triplicate.
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Additional file 1: Figure S1. MET and HGF expression. Real-time RT-PCR
analysis of HGF and MET transcript levels in U266 and RPMI-8226/S cells.
Figure S2. (A) NK-tert cells protect U266 cells from bortezomib-induced
cytotoxicity. (B) MET expression and HGF-dependent activity in serum
starved NK-tert cells.
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